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1.
Background and Objectives 70 Chronic Obstructive Pulmonary Disease (COPD) is characterised by symptoms of breathlessness and 71 cough, which worsen acutely during exacerbations. 1 COPD is known to be a heterogeneous disorder with 72 large variations in the risk of exacerbation across patients. 2 In clinical practice, a history of two or more 73 exacerbations and one severe exacerbation per year is used to guide therapeutic choices for exacerbation 74 prevention. 3 However, this approach is clinically limited owing to significant heterogeneity in risk even 75 within those who frequently exacerbate. 4 76 Prognostic clinical prediction tools enable personalised approaches to disease management. Despite 77 potential benefits, no such tool is routinely used in the clinical management of COPD. This is unlike 78 COPD-related mortality for which clinical scoring schemes such as the BODE index are available and 79 frequently used. 5 A 2017 systematic review by Guerra and colleagues identified 27 prediction tools for 80 COPD exacerbations. 6 Among these, only two reported on the validation of the model and none were 81 deemed ready for personalised COPD management in the clinic. 6 
82
Here, we describe a new model, the Acute COPD Exacerbation Prediction Tool (ACCEPT), to predict, at 83 an individual level, the rate and severity of COPD exacerbation and report on its performance in an 84 independent external cohort, and explain, using case studies, its potential clinical application. As a 85 decision tool, ACCEPT provides a personalised risk profile that allows clinicians to tailor treatment 86 regimens to the individual needs of the patients. 87
Methods

88
In reporting our prediction model, we have followed recommendations set forth by the Transparent 89
Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) 90 Statement. 7 91
Target population and source of data 92
We developed the model using data from COPD patients, without a prior or current history of asthma, and 93 who had experienced at least one exacerbation over the previous 12 months. We then externally validated 94 the model: 1) in COPD patients regardless of their exacerbation history, and 2) in a subset of COPD 95 patients with at least one exacerbation over the previous 12 months. 96 For discovery, we pooled data across all arms of three randomised controlled trials: Macrolide 97
Azithromycin to Prevent Rapid Worsening of Symptoms in COPD (MACRO) 8 , Simvastatin for the 98 Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) 9 , and the Optimal Therapy of 99 COPD to Prevent Exacerbations and Improve Quality of Life (OPTIMAL) 10 . We used Evaluation of 100 COPD Longitudinally to Identify Predictive Surrogate End-Points (ECLIPSE) 11 an independent 101 longitudinal COPD cohort studyfor external validation. The details of each of these studies have been 102 previously published. Briefly, the MACRO study 8 evaluated the effect of daily low-dose azithromycin 103 therapy on the rate of exacerbations in COPD patients; the STATCOPE study evaluated the effects of 104 daily simvastatin therapy on the rate of exacerbation 9 , and the OPTIMAL study evaluated the effects of 105 tiotropium-fluticasone-salmeterol on the rate of exacerbation compared with tiotropium-fluticasone and 106 tiotropium alone. 10 In all three trials, which comprised the development dataset, patients who had a 107 history of at least one exacerbation over the previous 12 months were recruited. ECLIPSE, on the other 108 hand, was a multicentre three-year, non-interventional observational study whose primary aim was to 109 characterise COPD phenotypes and identify novel markers of disease progression. 11 The ECLIPSE study 110 included patients irrespective of their prior history of an exacerbation. The outcomes of interest were the rates of exacerbations and severe exacerbations over one year. 115
Exacerbations were the primary outcome of all three trials and a major outcome measure of the ECLIPSE 116 study. All studies used a similar definition of exacerbations, which was based on the criteria endorsed by 117 the Global Initiative for Chronic Obstructive Lung Disease (GOLD) scientific committee. 3 Briefly, an 118 exacerbation was defined as an acute episode of intensified symptoms that required additional therapy. 3 
119
Mild exacerbations were defined as those that were treated with short-acting bronchodilators. Moderate 120 exacerbations were those that required the institution of systemic corticosteroids and/or antibiotics and 121 severe exacerbations were those that required an emergency department visit or a hospitalisation. 3,8-10 122
Predictors 123
To minimize the risk of bias, optimism, and overfitting, no data-driven variable selection was performed. 124
We pre-specified predictors based on clinical relevance and the availability of predictors in all the 125 datasets. Predictors included non-severe as well as severe exacerbations over the previous year, baseline 126 age, sex, smoking status, percent predicted post-bronchodilator forced expiratory volume in one second 127 (FEV1 % predicted 12 ), St. George's Respiratory Questionnaire (SGRQ) score, body mass index (BMI), and 128 the use of COPD and non-COPD medications as well as domiciliary oxygen therapy during the previous 129 12 months. COPD medications were defined as long-acting muscarinic receptor antagonists (LAMAs), 130 long-acting β2 agonists (LABAs), and inhaled corticosteroids (ICS). In addition to baseline medications, 131 the model adjusted for treatment assignment in the therapeutic trials (azithromycin in MACRO; statins in 132 STATCOPE; LABA/LAMA and ICS in OPTIMAL). To facilitate clinical implementation, a web 133 application was created (based on conversion factors that have been previously published), which enables 134 the use of a COPD Assessment Test (CAT) score in lieu of SGRQ. 13 135
Follow up 136
We applied administrative censoring at the one-year follow-up time for patients who had data beyond this 137 threshold. The decision to limit predictions to one year was made a priori based on the assumption that 138 predicting exacerbations over this time frame was relevant for clinical COPD management and that 139 prediction accuracy of the model would decrease substantially beyond one year. 140
Statistical analysis methods 141
We used a joint accelerated failure time and logistic model to characterise the rate and severity of 142 exacerbations. We have previously published the details of this approach elsewhere. 14 and uncertainty due to the differences in patients' specific exacerbation frequency and severity 151 (represented by the 95% prediction interval around the mean, the interval which has a 95% probability to 152 contain a future observation of a patient with the same predictors). Shrinkage methods were not applied 153
given the low risk of bias due to complete pre-specification of the model and the relatively high events 154
per predictor in the development dataset. 15 Because in this framework, the correlation between the 155 previous and future exacerbations rates is modelled through random-effect terms, a history of 156 exacerbation did not enter the model as a predictor. Instead, a Bayesian approach was employed to model 157 the distribution of future exacerbation rate and severity, given the exacerbation history of an individual 158 subject (Supplementary Appendix II). The availability of full exacerbation history in the external 159 validation cohort enabled validation of this approach. 160
External validation 161
We used the first year of follow-up data in ECLIPSE to establish an accurate 1-year history of 162 exacerbation for each patient. Next, we used the second year of follow-up to validate the model. The 163 model was validated first in the entire COPD cohort of ECLIPSE (n=1,819), and then in a subset of 164 COPD patients who had at least one exacerbation in the first year of follow-up (n=996). This subset was 165 similar to the population characteristics of the development dataset, while the full ECLIPSE cohort 166 enabled assessment of the generalisability of the model beyond patients with an exacerbation history. 167
We examined model calibration (the degree to which the predicted and actual risks or rates of 168 exacerbations aligned) and discrimination (the extent to which the model separated individuals with 169 different risks). 16 Calibration was assessed by comparing the predicted and observed exacerbation rates 170 across subgroups with differential risks, evaluating the calibration plots, and calculating Brier scores (i.e. 171 the mean squared error of forecast). Discrimination was assessed by calculating receiver operating 172 characteristic (ROC) curves, and the area-under-the-curve (AUC), and then comparing them using a 173
DeLong's test. 17 ROC and AUC calculations were based on the occurrence of two or more exacerbations 174 of any type, or one or more severe exacerbations. 3 175
Ethics Approval 176
The study was approved by the University of British Columbia/Providence Health Research Ethics Board 177 (H11-00786). 178
Results
179
Participants 180 Figure 1 presents the flowchart of sample selection. We excluded 96 patients who were either lost to 181 follow-up (n=33) or had missing values (n=63 Table 2>>  193 Supplementary Appendix III - Table S1 shows the distribution of baseline predictors among different 194 studies that were included in the development dataset. Notably, none of the STATCOPE participants had 195 a history of statin use because patients with cardiovascular comorbidities were excluded from this trial. 196
We assumed that missing values were missing at random and opted for a complete case analysis given 197 that only 2·58% of patients in the combined development dataset and 5·65% of patients in the validation 198 dataset had missing data (Supplementary Appendix II - Tables S2 and S3 ). 199 When validated against all patients in ECLIPSE (including those without an exacerbation history), 204
Model specification and performance 200
ACCEPT slightly overestimated their actual overall exacerbation rates (observed 1·20 events/year, 205 predicted 1·31 events/year) but was accurate for severe exacerbation rates (observed 0·27 events/year, 206 predicted 0·25 events/year, Figure 2A ). The same trend was observed in all major risk-factor subgroups 207 ( Figure 2A ) and in both men and women ( Figure 3A ). The Brier score was 0·20 for all exacerbations and 208 0·12 for severe exacerbations. In patients with an exacerbation history, ACCEPT showed robust overall 209 calibration: predicted annual exacerbation rate closely matched the observed rate for all exacerbations 210 (observed 1·82 events/year, predicted 1·80 events/year), severe exacerbations (observed 0·40 events/year, 211 predicted 0·37 events/year), and risk-factor subgroups ( Figure 2B ). Calibration plots comparing per decile 212 average rate of exacerbations showed good agreement between observed and predicted rates for both 213 female and male patients ( Figure 3B ). The Brier score was 0·17 for all exacerbations and 0·16 for severe 214 exacerbations. Similar results for the development dataset are provided in Supplementary Appendix IV. 215
In all COPD patients, the model had an AUC of 0·81 (95%CI 0·79-0·83) for ≥2 exacerbations and 0·77 216 (95%CI 0·74-0·80) for ≥1 severe exacerbation ( Figure 4A) . The corresponding AUCs for COPD patients 217 with an exacerbation history were 0·73 (95%CI 0·70-0·76) for two or more exacerbations and 0·74 218 (95%CI 0·70-0·78) for at least one severe exacerbation ( Figure 4B) . 219
Compared to the current practice, which relies exclusively on a prior history of exacerbation to predict 220 future risk of a exacerbation, ACCEPT demonstrated higher performance in predicting severe 221 exacerbations in all COPD patients (AUCACCEPT=0·77 vs. AUCEvent History=0·66, p<0·0001) and in the 222 subset who had a prior history of an exacerbation (AUCACCEPT=0·74 vs. AUCEvent History=0·67, p<0·0001). 223
Similarly, ACCEPT showed better performance for all exacerbations regardless of severity ( Figure 4) . 224 <<Figure 2, Figure 3 , Figure 4>>  225 
Discussion
226
While preventing exacerbations is a major goal in COPD care, there are no tools in practice that can 227 accurately predict the risk or rate of exacerbations in a given individual. Prior studies suggest that patients 228 with a previous history of an exacerbation are more likely to exacerbate in the future than those without. 2 
229
However, this approach is hampered by a relatively poor resolution, leading to large variations in risk 230 across subjects even among those who have the same history of exacerbations. Our framework builds 231 upon this well-accepted approach and extends its use by incorporating other clinical features that enable a 232 more accurate prediction. We used pooled data from three clinical trials to show that a model containing 233 simple clinical and demographic variables in aggregate can be used to predict the risk of exacerbation 234 with improved accuracy over 12 months of follow-up. 235
A 2017 systematic review of clinical prediction models for COPD exacerbations found that only two of 236 the 27 reviewed models -CODEX 18 and Bertens' model 19reported on any external validation. When 237 the availability of predictors and practical applicability were also taken into account, none of the models 238 were deemed ready for clinical implementation. 6 We are aware of only two additional prediction models 239 published after this reviewby Kerkhof 20 and Annavarapu 21that have reported external validation. 240 ACCEPT has several notable advantages compared with these models. Importantly, it is externally 241 validated in an independent cohort extending its generalisability beyond therapeutic clinical trials. 242 ACCEPT is also geographically generalisable because the external validation cohort contained data from 243 12 different countries across North America, Europe, and Oceania. In contrast, previous externally 244 validated models used geographically limited datasets: CODEX was Spanish 18 , Bertens' model was 245 Dutch 19 , Kerkhof's model was British 20 , and Annavarapu's model was based on cross-sectional 246 administrative data from a non-single-payer context in the United States. 21 Bertens' model, CODEX, and 247 models by Kerkhof and Annavarapu reported validation AUCs of 0·66 and 0·59, 0·74, and 0·77, 248 respectively. However, the independence of the validation dataset in Kerkhof's model was questioned as 249 it was selected from the same database as the developmental population. Annavarapu did not report 250 calibration at all, and overall, both models suffered from a lack of generalisability given the local nature 251 of the data that were available to the investigators. 252 ACCEPT predicts the rate and severity of exacerbations jointly. This is crucial to appropriately tailoring 253 treatments to an individual, as the more granular nature of the output in ACCEPT provides more detailed 254 prediction to assist clinicians in their decision making. For example, ACCEPT can predict the number of 255 exacerbations at a given time period, time to next exacerbation, and the probability of experiencing a 256 specific number of non-severe or severe exacerbations within a given follow-up time (up to one year). 257 This is in contrast to the logistic regression models used in a majority of previous clinical prediction 258 models, which allow prediction probabilities of having at least one exacerbation in a single time window. 6 259 Further, this framework can potentially be used for prognostic enrichment of randomised trials by 260 identifying patients who are more likely to exacerbate. Similar to asthma trials, the required sample size 261 and consequently the cost of large trials can be substantially reduced by using prediction models to recruit 262 patients above a certain threshold of expected exacerbation rate. 22, 23 263
Examples of Application in Clinic 264
Example 1 265
ACCEPT can combine predicted risk with effect estimates from randomised trials to enable personalised 266 treatment. For example, a benefit-harm analysis for roflumilast as preventive therapy for COPD 267 exacerbations reported that the benefits of roflumilast outweighed its potential harm when patients have a 268 severe exacerbation risk of at least 22% over a year. 24 Using data from this benefit-harm analysis, the 269 accompanying web app of ACCEPT can be used to inform therapeutic decisions on the use of roflumilast 270 for a given patient. Another example is in the potential use of preventative daily azithromycin therapy in 271 COPD. Azithromycin reduces exacerbation rate by 27%. 8 However, it is associated with increased risk of 272 hearing impairment and antimicrobial resistance and thus should be reserved for those at a high risk of 273 future exacerbations. 8 The accompanying web app illustrates this application by showing the risk of 274 exacerbations with and without daily azithromycin therapy in a given patient. Once care providers discuss 275 the risks of harm and benefits of the therapy and establish patient preference thresholds for the 276 benefit/harm trade-off, ACCEPT can be used to determine whether the preventive azithromycin therapy 277 for that individual reaches or surpasses this threshold. 278 <<Table 4>> 279
Example 2 280
ACCEPT generates nuanced predictions that allow clinicians to more accurately risk-stratify two patients, 281 who have an identical exacerbation history. For example, consider Patient A who has the following 282 characteristics: 57-years of age, male ex-smoker, with a chronic bronchitis phenotype, an FEV1 of 51% of 283 the predicted value (GOLD grade 2), BMI of 18 kg/m 2 , and a CAT score of 29. Now consider Patient B 284 who is 57 years of age, female ex-smoker with a chronic bronchitis phenotype, an FEV1 of 75% (GOLD 285 2), a CAT score of 10, and a BMI of 30 kg/m 2 . Both patients experienced two exacerbations within the 286 past year, one of which was severe, requiring a hospitalisation. Both are using LAMA, LABA, and ICS, 287 but not statins. The complete baseline characteristics of these two patients, as well as their ACCEPT 288 predictions, are shown in Table 4 . ACCEPT indicates that Patient A's 1-year probability of experiencing 289 a severe exacerbation is 29% (versus 18% for Patient B). His predicted severe exacerbation rate is 0.6 290 events/year (versus 0.3 events/year for Patient B). Based on the benefit-harm analysis for roflumilast 24 , 291 the web app for ACCEPT predicts that roflumilast is likely to provide a net benefit to Patient A (net 292 benefit probability>80%) but not for Patient B (net benefit probability<20%). 293
Limitations 294
The pooled trial data we used to develop the model lacked data on certain variables such as comorbidities, 295 vaccination, blood markers (e.g. eosinophil count), and socio-economic status. As such, these predictors 296 could not be incorporated into the model. Moreover, the developmental dataset did not contain individuals 297 without exacerbations in the previous year; however, the model performed robustly in an external 298 validation dataset that included such patients. Neither the developmental nor the validation datasets 299 included patients with mild (GOLD I) severity and as such, we could not establish the accuracy of 300 predictions for this subgroup. Additionally, our model may not be generalisable to COPD patients with a 301 history of asthma, lifetime non-smokers, patients younger than 40 or older than 80 years of age, or 302 populations outside North America, Europe, and Oceania. Model updating and re-examination of its 303 external validity will be necessary when new sources of data become available. 25 
304
Compared to simple scoring systems such as the BODE index that can be manually calculated, ACCEPT 305 requires relatively sophisticated computational analysis. While parsimonious models are useful at the 306 bedside, given the complexity of processes involved in the pathogenesis of COPD exacerbations, we 307 believe such tools will have limited resolution. Given the proliferation of hand-held computational 308 devices in clinical practice and the wide availability of clinical parameters that are contained in the model, 309
ACCEPT is usable clinically. This is facilitated through its availability as a web app, a spreadsheet, or the 310 R package 'accept'. 26 
311
We emphasise that estimates in our model are predictive and should not be interpreted as "causal". The 312 observed association between being a smoker and a having a lower exacerbation rate (hazard ratio 0·82, 313 95%CI 0·73-0·93) is one such example. Smoking is likely a marker of disease severity with sicker 314 patients less likely to smoke than those with milder disease. As such, the information in the smoking 315 status variable has high predictive value for the tendency towards exacerbation but is not causally 316 interpretable. 317
How to Access the Model 318
An easy-to-use web application for ACCEPT is available at http://resp.core.ubc.ca/ipress/accept. For any 319 individual patient, the web app predicts 1) the exacerbation risk within the next 12 months, 2) the annual 320 rate of exacerbations, and 3) the probability of experiencing any given number of exacerbations. All 321 outcomes are reported separately for overall and severe exacerbations. 322
Additionally, we provide an R package 26 , a spreadsheet template, public application programming 323 interfaces (APIs), and additional code at http://resp.core.ubc.ca/research/Specific_Projects/accept. 324 Abbreviations: CI, confidence interval; FEV1, % predicted forced expiratory volume in 1 second using Hankinson's method 12 ;; SGRQ, St. George's Respiratory Questionnaire; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta antagonist; ICS, inhaled corticosteroids; BMI, body mass index. a All p-values and confidence limits were computed from the final Hessian matrix based on a t distribution with default degrees of freedom (number of subjects minus number of random effects) in SAS NLMIXED. b Binary predictor for medication use in the previous 12 months. c Between 0 and 100, with a higher score indicating worse status. In line with GOLD recommendations, Area-under-the-curve (AUC) is shown for predicting at least two exacerbations and at least of severe exacerbation. DeLong's test for two correlated ROC curves was used to produce p-values.
Conclusions
